AU2019347730A1 - Method of providing safe administration of an anti-CD154 antibody - Google Patents

Method of providing safe administration of an anti-CD154 antibody Download PDF

Info

Publication number
AU2019347730A1
AU2019347730A1 AU2019347730A AU2019347730A AU2019347730A1 AU 2019347730 A1 AU2019347730 A1 AU 2019347730A1 AU 2019347730 A AU2019347730 A AU 2019347730A AU 2019347730 A AU2019347730 A AU 2019347730A AU 2019347730 A1 AU2019347730 A1 AU 2019347730A1
Authority
AU
Australia
Prior art keywords
antibody
binding fragment
antigen binding
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019347730A
Other languages
English (en)
Inventor
Jocelyn LEU
Alexa PIANTONE
Donald Raible
Mark Rigby
Nina Chi Sabins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AU2019347730A1 publication Critical patent/AU2019347730A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2019347730A 2018-09-24 2019-09-24 Method of providing safe administration of an anti-CD154 antibody Abandoned AU2019347730A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862735529P 2018-09-24 2018-09-24
US62/735,529 2018-09-24
US201962826131P 2019-03-29 2019-03-29
US62/826,131 2019-03-29
PCT/US2019/052558 WO2020068723A1 (en) 2018-09-24 2019-09-24 Method of providing safe administration of an anti-cd154 antibody

Publications (1)

Publication Number Publication Date
AU2019347730A1 true AU2019347730A1 (en) 2021-03-25

Family

ID=69950835

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019347730A Abandoned AU2019347730A1 (en) 2018-09-24 2019-09-24 Method of providing safe administration of an anti-CD154 antibody

Country Status (6)

Country Link
US (1) US20210317220A1 (https=)
EP (1) EP3856246A4 (https=)
JP (1) JP2022502380A (https=)
CN (1) CN112770774A (https=)
AU (1) AU2019347730A1 (https=)
WO (1) WO2020068723A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115812080A (zh) * 2020-07-08 2023-03-17 瑞泽恩制药公司 含有抗ctla-4抗体的稳定调配物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US9028826B2 (en) * 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
AU2012323316B2 (en) * 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
IL256800B2 (en) * 2015-07-14 2023-04-01 Immunext Inc An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy
PE20180802A1 (es) * 2015-08-05 2018-05-09 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos

Also Published As

Publication number Publication date
CN112770774A (zh) 2021-05-07
WO2020068723A1 (en) 2020-04-02
US20210317220A1 (en) 2021-10-14
JP2022502380A (ja) 2022-01-11
EP3856246A4 (en) 2022-07-20
EP3856246A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
DK2406284T5 (en) ANTI-BCMA ANTIBODIES
TWI857389B (zh) 治療發炎症狀的方法
AU2019385331B2 (en) Antagonistic CD40 monoclonal antibodies and uses thereof
Eskiocak et al. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
EP3359567A2 (en) Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
US20130315913A1 (en) Anti-light antibody therapy for inflammatory bowel disease
JP2020531854A (ja) 癌の治療および診断のためのｔｉｍ−３アンタゴニスト
CN113784985A (zh) T1dm和胰岛炎的治疗中使用的抗cd40抗体
US20210380700A1 (en) De-adcc/cdc functions of antibodies and their applications
WO2023172989A2 (en) Epo receptor agonists and antagonists
TW202311293A (zh) 免疫療法之組合及其用途
US20210317220A1 (en) Method of providing safe administration of an anti-cd154 antibody
AU2021352981A1 (en) Anti-cd94 antibodies and methods of use thereof
CA3181677A1 (en) Combination therapy comprising anti-cd137 antibodies
KR20220012918A (ko) 항-cd40 항체의 안전한 투여를 제공하는 방법
HK40050403A (en) Method of providing safe administration of an anti-cd154 antibody
AU2023272836A1 (en) Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
Wang Zhaohui Wanga, Shannon G. Prattsa, Huiping Zhanga, Philip J. Spencera, Ruichao Yua, Makoto Tonsho, Jigesh A. Shah, Tatsu Tanabe, Harrison R. Powell, Christene A. Huang, Joren C. Madsen, David H. Sachs, Zhirui Wang
WO2018083080A2 (en) Nkp46 ligand
HK1166333B (en) Anti-bcma antibodies

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period